Advertisement

Reproducibility over time of the urinary diclofenac/4′-OH diclofenac ratio among differentCYP2C9 genotypes

  • Pedro Dorado
  • Roland Berecz
  • Macarena C. Cáceres
  • Idilio Conzález
  • Adrián Llerena
Article

Summary

Diclofenac has been used for the evaluation of CYP2C9 activityin vitro as well asin vivo with varying results. The present study was aimed at evaluating the reproducibility of the urinary diclofenac/4′-OH diclofenac ratio among differentCYP2C9 genotypes in healthy volunteers. The study ofCYP2C9 genotypes in the family of aCYP2C9*3/*3 subject is also reported. The urinary diclofenac/4′-OH diclofenac ratio was determined on two occasions within a period of 9–12 months, and was found to be correlated (r=0.83,p<0.05). The mean (±SD) of diclofenac/4′-OH diclofenac ratio was 1.5 times higher among subjects carryingCYP2C9*3 allele (CYP2C9*1/*3 andCYP2C9*2/*3 genotypes) (0.91±0.28), compared toCYP2C9*1/*1 subjects (0.60±0.11). The results show that the urinary diclofenac/4′-OH diclofenac ratio might be used to study CYP2C9 in humans. The data agree with previous studies showing that theCYP2C9*3 allelic variant seems to cause a decreased CYP2C9 hydroxylation capacity.

Keywords

CYP2C9 diclofenac losartan cytochrome P450 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Xie H.G., Prasad H.C., Kim R.B., Stein C.M. (2002):CYP2C9 allelic variants: ethnic distribution and functional significance. Adv. Drug. Deliv. Rev., 54, 1257–1270.CrossRefPubMedGoogle Scholar
  2. 2.
    Miners J.O., Birkett D.J. (1998): Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br. J. Clin. Pharmacol., 45, 525–538.CrossRefPubMedGoogle Scholar
  3. 3.
    Lee C.R., Goldstein J.A., Pieper J. (2002): Cytochrome P4502C9 polymorphisms: a comprehensive review of the in vitro and human data. Pharmacogenetics, 12, 251–263.CrossRefPubMedGoogle Scholar
  4. 4.
    Shimamoto J., Ieiri I., Urae A., et al. (2000): Lack of differences in diclofenac (a substrate for CYP2C9) pharmacokinetics in healthy volunteers with respect to the singleCYP2C9*3 allele. Eur. J. Clin. Pharmacol., 56, 65–68.CrossRefPubMedGoogle Scholar
  5. 5.
    Morin S., Loriot M.A., Poirier J.M., et al. (2001): Is diclofenac a valuable CYP2C9 probe in humans? Eur. J. Clin. Pharmacol., 56, 793–797.CrossRefPubMedGoogle Scholar
  6. 6.
    Yasar Ü., Eliasson E., Forslund-Bergengren C., et al. (2001): The role ofCYP2C9 genotype in the metabolism of diclofenac in vivo and in vitro. Eur. J. Clin. Pharmacol., 57, 729-Xie 735.CrossRefPubMedGoogle Scholar
  7. 7.
    Dorado P., Berecz R., Cáceres M.C., LLerena A. (2003): Analysis of diclofenac and its metabolites by high-performance liquid chromatography: Relevance ofCYP2C9 genotypes in diclofenac urinary metabolic ratios. J. Chromatogr B., 789, 437–442.CrossRefGoogle Scholar
  8. 8.
    Dorado P., Berecz R., Norberto M.J., Yasar Ü., Dahl M.-L., LLerena A. (2003):CYP2C9 genotypes and diclofenac metabolism in Spanish healthy volunteers. Eur. J. Clin. Pharmacol. (in press).Google Scholar
  9. 9.
    Yasar Ü., Forslund-Bergengren C., Tybring G., et al. (2002): Pharmacokinetics of losartan and its metabolite E-3174 in relation to theCYP2C9 genotype. Clin. Pharmacol. Ther., 71, 89–98.CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2003

Authors and Affiliations

  • Pedro Dorado
    • 1
  • Roland Berecz
    • 1
  • Macarena C. Cáceres
    • 1
  • Idilio Conzález
    • 1
  • Adrián Llerena
    • 1
    • 2
  1. 1.Department of Pharmacology and Psychiatry, Faculty of MedicineUniversity of ExtremaduraBadajozSpain
  2. 2.Department of Medical Sciences, Faculty of Health SciencesUniversity of Beira InteriorCovilhãPortugal

Personalised recommendations